Goldman Sachs
ORMP icon

Goldman Sachs’s Oramed Pharmaceuticals ORMP Stock Holding History

Goldman Sachs’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
+253,293
New +$1.01M ﹤0.01% 5061
2023
Q4 		– Sell
-153,618
Closed -$401K – 5776
2023
Q3 		$401K Buy
153,618
+62,703
+69% +$197K ﹤0.01% 4751
2023
Q2 		$325K Sell
90,915
-10,039
-10% -$32.2K ﹤0.01% 4973
2023
Q1 		$220K Buy
100,954
+84,447
+512% +$268K ﹤0.01% 5258
2022
Q4 		$199K Sell
16,507
-38,395
-70% -$298K ﹤0.01% 5311
2022
Q3 		$355K Buy
54,902
+26,539
+94% +$215K ﹤0.01% 5201
2022
Q2 		$130K Sell
28,363
-41,820
-60% -$223K ﹤0.01% 5783
2022
Q1 		$607K Sell
70,183
-46,851
-40% -$480K ﹤0.01% 5190
2021
Q4 		$1.67M Buy
117,034
+97,266
+492% +$2.03M ﹤0.01% 4404
2021
Q3 		$435K Sell
19,768
-15,287
-44% -$260K ﹤0.01% 5275
2021
Q2 		$469K Buy
35,055
+15,300
+77% +$175K ﹤0.01% 5261
2021
Q1 		$201K Buy
+19,755
New +$162K ﹤0.01% 5647

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Goldman Sachs's ORMP Position: Q2 2026 in Review

Goldman Sachs opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 253,293 shares worth $1.22M. The stake represents ﹤0.01% of the portfolio and ranks #5061 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in ORMP as recently as Q3 2023.

Goldman Sachs first reported a position in ORMP in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.67M in Q4 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Goldman Sachs held 253,293 shares of Oramed Pharmaceuticals worth $1.22M as of Q2 2026.
  • Oramed Pharmaceuticals was a new Goldman Sachs position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5061 holding.
  • Goldman Sachs first reported a position in Oramed Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • Goldman Sachs's Oramed Pharmaceuticals position peaked at $1.67M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.